{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:25:36Z","timestamp":1793111136305,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.arbres.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T16:22:26Z","timestamp":1710778946000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis\/Pre-COPD: Distinct Meta-analyses"],"prefix":"10.1016","volume":"60","author":[{"given":"Alberto","family":"Papi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Mawass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Aljama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Contoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2024.03.010_bib0280","unstructured":"World Health Organization \u2013 chronic obstructive pulmonary disease (COPD). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd) [last accessed 20.12.23]."},{"key":"10.1016\/j.arbres.2024.03.010_bib0285","series-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2024"},{"key":"10.1016\/j.arbres.2024.03.010_bib0290","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0143-2023","article-title":"From treatable traits to GETomics in airway disease: moving towards clinical practice","volume":"33","author":"Papi","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2024.03.010_bib0295","doi-asserted-by":"crossref","first-page":"106572","DOI":"10.1016\/j.rmed.2021.106572","article-title":"Moving towards a treatable traits model of care for the management of obstructive airways diseases","volume":"187","author":"Agusti","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0300","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaip.2023.01.011","article-title":"Treatable traits in airway disease: from theory to practice","volume":"11","author":"Agusti","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.arbres.2024.03.010_bib0305","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201511-2210OC","article-title":"The presence of chronic mucus hypersecretion across adult life in relation to chronic obstructive pulmonary disease development","volume":"193","author":"Allinson","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0310","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.2147\/COPD.S330817","article-title":"Treatable traits in COPD \u2013 a proposed approach","volume":"16","author":"Cardoso","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2024.03.010_bib0315","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1164\/rccm.202008-3328PP","article-title":"From GOLD 0 to Pre-COPD","volume":"203","author":"Han","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0320","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision","volume":"206","author":"Celli","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0325","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.hrtlng.2016.12.004","article-title":"The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: a meta-analysis and systematic review","volume":"46","author":"Fowdar","year":"2017","journal-title":"Heart Lung"},{"key":"10.1016\/j.arbres.2024.03.010_bib0330","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.21037\/apm-21-1138","article-title":"Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease","volume":"10","author":"Jiang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0335","first-page":"351","article-title":"Effect of high\/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"11","author":"Shen","year":"2014","journal-title":"COPD"},{"key":"10.1016\/j.arbres.2024.03.010_bib0340","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.arbres.2024.03.010_bib0345","first-page":"775","article-title":"Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis","volume":"1","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2024.03.010_bib0350","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1037\/1082-989X.3.4.486","article-title":"Fixed- and random-effects models in meta-analysis","volume":"3","author":"Hedges","year":"1998","journal-title":"Psychol Methods"},{"key":"10.1016\/j.arbres.2024.03.010_bib0355","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0360","doi-asserted-by":"crossref","first-page":"377","DOI":"10.6028\/jres.087.022","article-title":"Consensus values and weighting factors","volume":"87","author":"Paule","year":"1982","journal-title":"J Res Natl Bur Stand (1977)"},{"key":"10.1016\/j.arbres.2024.03.010_bib0365","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/jrsm.1404","article-title":"Methods for estimating between-study variance and overall effect in meta-analysis of odds ratios","volume":"11","author":"Bakbergenuly","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.arbres.2024.03.010_bib0370","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.arbres.2024.03.010_bib0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.arbres.2024.03.010_bib0380","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2288-4-17","article-title":"Meta-analytic methods for pooling rates when follow-up duration varies: a case study","volume":"4","author":"Guevara","year":"2004","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.arbres.2024.03.010_bib0385","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/0272989X9501500112","article-title":"Meta-analytic tools for medical decision making: a practical guide","volume":"15","author":"Hasselblad","year":"1995","journal-title":"Med Decis Making"},{"key":"10.1016\/j.arbres.2024.03.010_bib0390","series-title":"Cochrane handbook for systematic reviews of interventions version 6.3: Cochrane","author":"Higgins","year":"2022"},{"key":"10.1016\/j.arbres.2024.03.010_bib0395","series-title":"Cochrane handbook for systematic reviews of interventions, version 5.1.0","year":"2011"},{"key":"10.1016\/j.arbres.2024.03.010_bib0400","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"10.1016\/j.arbres.2024.03.010_bib0405","doi-asserted-by":"crossref","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.arbres.2024.03.010_bib0410","first-page":"405","article-title":"Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases","volume":"64","author":"Boman","year":"1983","journal-title":"Eur J Respir Dis"},{"key":"10.1016\/j.arbres.2024.03.010_bib0415","first-page":"467","article-title":"Confronto tra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica. Esperienza controllata double-blind","volume":"140","author":"Borgia","year":"1981","journal-title":"Gaz Med It"},{"key":"10.1016\/j.arbres.2024.03.010_bib0420","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00606554","article-title":"A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis","volume":"09","author":"Grassi","year":"1976","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arbres.2024.03.010_bib0425","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0954-6111(05)80337-3","article-title":"Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis","volume":"88","author":"Hansen","year":"1994","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0430","article-title":"Langzeittherapie mit Acetylcystein Ret2 rd-Tab7 alter\u2019 bei Patienten mit chronischer Bronchitis Eine doppelblinde-placebokontrollierte","volume":"25","author":"Meister","year":"1986","journal-title":"Studie Forum des Praktischen und Allgemein-Arztes"},{"key":"10.1016\/j.arbres.2024.03.010_bib0435","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0007-0971(87)90182-3","article-title":"Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis","volume":"81","author":"Parr","year":"1987","journal-title":"Br J Dis Chest"},{"key":"10.1016\/j.arbres.2024.03.010_bib0440","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/030006058401200312","article-title":"Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study","volume":"12","author":"Jackson","year":"1984","journal-title":"J Int Med Res"},{"key":"10.1016\/j.arbres.2024.03.010_bib0445","first-page":"93","article-title":"Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study","volume":"111","author":"Babolini","year":"1980","journal-title":"Eur J Respir Dis Suppl"},{"key":"10.1016\/j.arbres.2024.03.010_bib0450","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1183\/09031936.93.01040351","article-title":"Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis","volume":"1","author":"Rasmussen","year":"1988","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2024.03.010_bib0455","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.rmed.2008.11.003","article-title":"Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis","volume":"103","author":"Schermer","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0460","first-page":"12","article-title":"Effect of oral N-acetylcysteine in COPD \u2013 a randomised controlled trial","volume":"14","author":"Bachh","year":"2007","journal-title":"JK \u2013 Practitioner"},{"key":"10.1016\/j.arbres.2024.03.010_bib0465","first-page":"4809","article-title":"A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease","volume":"26","author":"Buha","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.arbres.2024.03.010_bib0470","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2024.03.010_bib0475","first-page":"799","article-title":"High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial","volume":"11","author":"Johnson","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2024.03.010_bib0480","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/rmed.2001.1066","article-title":"Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease","volume":"95","author":"Kasielski","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0485","first-page":"P2522","article-title":"Long-term administration of N-acetylcysteine reduces the number of acute exacerbation episodes in subjects with chronic obstructive pulmonary disease: report of the Breathe study","volume":"381s","author":"Nowak","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2024.03.010_bib0490","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000029447","article-title":"N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD","volume":"66","author":"Pela","year":"1999","journal-title":"Respiration"},{"key":"10.1016\/j.arbres.2024.03.010_bib0495","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1378\/chest.12-2357","article-title":"High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study","volume":"144","author":"Tse","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2024.03.010_bib0500","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0505","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/thx.40.11.832","article-title":"Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee","volume":"40","author":"McGavin","year":"1985","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2024.03.010_bib0510","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1183\/16000617.00002215","article-title":"Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis","volume":"24","author":"Cazzola","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2024.03.010_bib0515","first-page":"CD001287","article-title":"Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease","volume":"5","author":"Poole","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2024.03.010_bib0520","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1505971","article-title":"Clinical significance of symptoms in smokers with preserved pulmonary function","volume":"374","author":"Woodruff","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0525","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MCP.0000000000000854","article-title":"Pre-chronic obstructive pulmonary disease: a pathophysiologic process or an opinion term?","volume":"28","author":"Mkorombindo","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.arbres.2024.03.010_bib0530","first-page":"4846336","article-title":"N-acetyl-l-cysteine protects airway epithelial cells during respiratory syncytial virus infection against mucin synthesis, oxidative stress, and inflammatory response and inhibits HSPA6 expression","volume":"2022","author":"Chi","year":"2022","journal-title":"Anal Cell Pathol (Amst)"},{"key":"10.1016\/j.arbres.2024.03.010_bib0535","doi-asserted-by":"crossref","first-page":"e48037","DOI":"10.1371\/journal.pone.0048037","article-title":"Respiratory syncytial virus inhibits ciliagenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-acetylcysteine","volume":"7","author":"Mata","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2024.03.010_bib0540","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2011.05.014","article-title":"N-acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)","volume":"82","author":"Mata","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.arbres.2024.03.010_bib0545","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1183\/09031936.03.00018003","article-title":"Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats","volume":"22","author":"Mata","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2024.03.010_bib0550","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/mi.2010.62","article-title":"Reactive oxygen species mediate inflammatory cytokine release and EGFR-dependent mucin secretion in airway epithelial cells exposed to Pseudomonas pyocyanin","volume":"4","author":"Rada","year":"2011","journal-title":"Mucosal Immunol"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289624000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289624000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T19:59:01Z","timestamp":1714593541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289624000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0300289624000693"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2024.03.010","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis\/Pre-COPD: Distinct Meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEPAR.","name":"copyright","label":"Copyright"}]}}